Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
Relieve severe toothache with clove oil. It works wonders. The link to buy the oil is: https://amzn.to/2F4hYtK
To read the full review please visit: https://bestoralbelectrictoothbrush.com/how-to-treat-a-toothache-with-this-magically-scientific-formula/
There are a couple of home remedies you can try right away to hold off the pain until you get the clove oil. If it persists for longer than a week then go and seek professional help.
Tornado and high winds are some of the most destructive forces of nature. While tornadoes are frequent in the Great Plains, South, and Midwest, there is no state in the country that isn’t at risk. As the nation’s largest property insurer, State Farm wants to make sure you and your family are prepared for the destructive and potentially deadly force of a tornado.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7452831-state-farm-weather-preparedness/
Did you use the plywood from your hurricane shutters to build a tree house or use your garage door brace to hold up the bird feeder? If so there’s a good chance your home may not be hurricane ready.
Being properly prepared is paramount during hurricane season. To learn more about how to protect yourself and your property, visit State Farm Learning Center. It can make a big difference to your safety, security and survival. Is your property hurricane ready?
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65822-state-farm-severe-weather-disaster-preparedness/
The Federal Alliance for Safe Homes (FLASH)® encourages families in the Northwest to understand their unique winter flood risk and prepare now to protect property and possessions from flood damage.
Floods are a year-round hazard, and the risks do not end when cold weather begins. Heavy seasonal rains and snowmelt often lead to flooding during the winter months. Even areas that receive less snow and rain this winter season might experience drought-like conditions that ultimately can lead to flash flooding when it does rain.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59559-federal-alliance-for-safe-homes-flash-winter-weather-flood-risk
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that The New England Journal of Medicine today published results from Cohort B of The PARTNER Trial, which studied the Edwards SAPIEN transcatheter heart valve for the treatment of severe aortic stenosis. The results of the trial successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/44227/
On January 12, 2010, a devastating earthquake hit Haiti, killing more than 230,000 people and displacing approximately 1.5 million. Children were orphaned; families were left homeless; and homes, schools and hospitals destroyed. Five years later, SOS Children’s Villages, the world’s largest organization providing care for orphaned and abandoned children, remains unwavering in its ongoing, long-term commitment to the people of Haiti.
“Efforts to rebuild the most affected areas move at a slow place, and the need to support vulnerable children and families remains high. Many of the children and families who survived the earthquake lost everything and experienced severe emotional trauma,” said Lynn Croneberger, CEO of SOS Children’s Villages – USA. “In 2010, we made a strong commitment to support these survivors. Thanks to generous donors and the Government of Haiti, we are able to continue to provide support to Haiti’s most vulnerable.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409351-sos-children-village-milestones/
A recent survey conducted by DSM Nutritional Products found that 83 percent of adults in the U.S. believe worsening eye health is inevitable with age. What many people don’t realize is that there’s a connection between healthy eyes and proper nutrition, and it goes beyond eating carrots.
According to Dr. Kimberly Reed, optometrist and Ocular Nutrition Society board member, “Incorporating certain nutrients into the diet can support a lifetime of healthy vision and help protect against serious conditions, including cataracts and age-related macular degeneration (AMD). The latter affects more than 2 million Americans and can lead to severe visual impairment.”
To view Multmedia News Release, go to: http://www.multivu.com/players/English/7129751-dsm-nutritional-products-eye-health-survey/
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck for Mothers has launched programs aimed at decreasing the number of women across the United States who die from or suffer severe complications related to pregnancy and childbirth.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62776-merck-for-mothers-working-to-reduce-maternal-mortality-rate
One to six in 1,000 children in the United States are born with severe to profound hearing loss.1 For a parent, that diagnosis can be life altering, and they are in need of help, information and support. Today, Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces IWantYouToHear.com as part of its ongoing commitment to parents seeking treatment options for their child’s severe to profound hearing loss.
For many parents with a child who has received a hearing loss diagnosis, the wish for their child is immediate and clear: “I want you to hear.” They want their child to hear the birds and their favorite songs, learn to develop speech and language, and most of all, they want their child to hear them say “I love you.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7658351-cochlear-americas-i-want-you-to-hear/
